Right place right time: the role of immunotherapy in patients with locally advanced gastric/gastroesophageal junction adenocarcinoma.

J Gastrointest Oncol · 2025 · PMC12780630 · PMID 41522754

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

a favorable trendno p-value reported

MATTERHORN is the first phase 3 trial to show a statistically significant improvement in EFS and a favorable trend in OS with perioperative durvalumab plus FLOT.

also in 993 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.